ArticleBMC public health2026
Pattern and predictors of drug resistance and treatment outcome in tuberculosis patients at the centers of programmatic management of drug-resistant tuberculosis in Lahore, Pakistan.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobally, the prevalence of drug-resistant (DR-TB) tuberculosis is rising, and Pakistan is currently one of the nations with the highest burden. It is imperative to track changes in the prevalence of DR-TB, particularly the extensively drug-resistant (XDR-TB) tuberculosis, and identify the pattern of treatment outcome.
objectiveTo identify the pattern and predictors of drug resistance and treatment outcome in tuberculosis patients at the Centers for Programmatic Management of Drug-resistant Tuberculosis (PMDT) in Lahore, Pakistan.
methodA cross-sectional analytical study was done in three PMDT centers (Programmatic Management of Drug-resistant Tuberculosis) in District Lahore. Secondary data of 387 were accessed, including files of patients of all ages and both genders enrolled during 2021. Data was collected from April to July, 2023. SPSS version 24 was used to enter the data. Information on drug resistance categories, pattern, socio-demographic and disease-related factors, adverse events, and treatment outcomes were gathered.
resultsRR resistance was found in 32.8% (127/387), MDR in 45.0% (174/387), Pre-XDR-TB in 21.2% (82/387) and XDR-TB in the remaining 1.0% (4/387). Drug-resistant TB was Pulmonary in 373/387 (96.4%) patients, while 3.6% were extra-pulmonary. 54.3% (210/387) males were enrolled with Drug-Resistant Tuberculosis with pre-dominantly RR-TB 38.1% (80/387). The mean age of 387 drug-resistant TB patients was 38.43 with SD of 17.190. Age (p-value = 0.007) and gender (p-value = 0.047) have been found significantly associated with the DRTB groups. The highest proportion (44.6%) of all types of comorbidities were observed in the MDR-TB group and being lowest (18.5%) in Pre-XDR/XDR TB group. Prior TB history was present in 65.1% (252/387) patients with majority in MDR group (46.4%). DR-TB arthralgia was the most common adverse event at 21%. The highest number of adverse events (adverse event = 208) were observed in DRTB cases who were administered with Pyrazinamide drug and the least adverse events were observed among DRTB cases taking Amikacin (adverse event = 9) and MFX (adverse event = 2). In 53.6% patients the treatment was successful, while 15.3% died.
conclusionDrug resistant tuberculosis patients had a high death rate and multiple adverse events associated with the treatment. Multipronged strategies need to be designed to improve treatment success, minimize adverse events and increase awareness about DR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.